Cadence Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Cadence Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-33,286	Closed	-$665K	–	662
2018 Q2	$665K	Buy	33,286 +3,593	+12%	+$66.4K	0.04%	460
2018 Q1	$520K	Buy	29,693 +933	+3%	+$19.8K	0.03%	498
2017 Q4	$709K	Buy	28,760 +2,072	+8%	+$50.5K	0.05%	435
2017 Q3	$689K	Buy	+26,688	New	+$715K	0.04%	443
2017 Q2	–	Sell	-7,910	Closed	-$236K	–	658
2017 Q1	$236K	Buy	+7,910	New	+$228K	0.02%	631

Other funds holding ACRS

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cadence Capital Management's ACRS Position: Q3 2018 in Review

Cadence Capital Management sold out of Aclaris Therapeutics (ACRS) in Q3 2018, closing a stake of 33,286 shares — an estimated $665K sold.

Cadence Capital Management first reported a position in ACRS in Q1 2017 and held it in 5 quarters. The position peaked at $709K in Q4 2017. 86 funds tracked by Wall St. Rank hold ACRS as of Q3 2018.

Cadence Capital Management reported no remaining Aclaris Therapeutics position as of Q3 2018 after selling out during the quarter.
Cadence Capital Management sold 33,286 Aclaris Therapeutics shares in Q3 2018, an estimated $665K.
Cadence Capital Management first reported a position in Aclaris Therapeutics in Q1 2017 and held it in 5 quarters.
Cadence Capital Management's Aclaris Therapeutics position peaked at $709K in Q4 2017.
86 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2018.

Based on Cadence Capital Management's 13F filing for Q3 2018, filed 2 Nov 2018.